Neopharmed Gentili

News

Two boxes of Orladeyo on a blue background

Neopharmed buys Euro rights to BioCryst's HAE drug Orladeyo

Neopharmed Gentili buys BioCryst's hereditary angioedema drug Orladeyo in Europe, the first stage of an international expansion for the Italian firm.

News

JPM: AbbVie pays $650m upfront for RemeGen cancer drug

AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks